Evidence map›Paper›PMID 34680805›Full record

ArticleAntibiotics (Basel, Switzerland)2021

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR)

Marianna Meschiari, Gabriella Orlando, Shaniko Kaleci, Vincenzo Bianco, Mario Sarti, Claudia Venturelli, Cristina Mussini

Open access · goldAbstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Source Control inOpen forum infectious diseases · 2026
    Article
  3. Article
  4. Observational
  5. Article
  6. Microbiology spectrum · 2024
    Article
  7. The small RNA PrrH aggravatesMicrobiology spectrum · 2024
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Marianna MeschiariInfectious Disease Clinic, Policlinico University Hospital, 41122 Modena, Italy.ORCID 0000-0002-1254-9995
Gabriella OrlandoInfectious Disease Clinic, Policlinico University Hospital, 41122 Modena, Italy.
Shaniko KaleciClinical and Experimental Medicine, University of Modena and Reggio Emilia, 41122 Modena, Italy.ORCID 0000-0002-1166-2961
Vincenzo BiancoInfectious Disease Clinic, Cotugno Hospital, 80131 Naples, Italy.
Mario SartiClinical Microbiology Laboratory, University of Modena and Reggio Emilia, 41122 Modena, Italy.
Claudia VenturelliClinical Microbiology Laboratory, University of Modena and Reggio Emilia, 41122 Modena, Italy.
Cristina MussiniInfectious Disease Clinic, Policlinico University Hospital, 41122 Modena, Italy.
Azienda Ospedaliero-Universitaria di Modena · ITUniversity of Modena and Reggio Emilia · ITOspedale D. Cotugno · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A retrospective case-control study was conducted at Modena University Hospital from December 2017 to January 2019 to identify risk factors and predictors of MDR/XDR

Indexed as

carbapenems useceftazidime/avibactamceftolozane/tazobactamcombined resistance to ceftazidime/avibactam and ceftolozane/tazobactamcombining antimicrobial stewardship and infection controldifficult to treat pathogenhospital acquired infectionsMDR/XDR Pseudomonas aeruginosa

Identifiers

PMID34680805
PMCPMC8532599
OpenAlexW3203828876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.